Nektar Therapeutics (NASDAQ: NKTR) is 121.24% higher on its value in year-to-date trading and has touched a low of $0.41 and a high of $1.47 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NKTR stock was last observed hovering at around $1.31 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $1.25, the stock is 30.40% and 55.25% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.07 million and changing -4.58% at the moment leaves the stock 98.91% off its SMA200. NKTR registered 57.99% gain for a year compared to 6-month gain of 131.05%. The firm has a 50-day simple moving average (SMA 50) of $0.52 and a 200-day simple moving average (SMA200) of -$0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 37.50% loss in the last 1 month and extending the period to 3 months gives it a 112.95%, and is 31.58% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.35% over the week and 9.78% over the month.
Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $229.53M and $90.12M in sales. Profit margin for the company is -306.31%. Distance from 52-week low is 202.96% and -14.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-80.69%).
Nektar Therapeutics quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $15.34M over the same period.The EPS is expected to grow by 38.97% this year, but quarterly earnings will post -25.10% year-over-year.
Nektar Therapeutics (NKTR) Top Institutional Holders
155 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 67.81% of the company’s shares. The shares outstanding are 191.38M, and float is at 178.15M with Short Float at 1.41%. Institutions hold 67.25% of the Float.
The top institutional shareholder in the company is Deep Track Capital, Lp with over 17.97 million shares valued at $10.34 million. The investor’s holdings represent 9.45% of the NKTR Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 12.06 million shares valued at $6.93 million to account for 6.34% of the shares outstanding. The other top investors are Citadel Advisors Llc which holds 9.7 million shares representing 5.10% and valued at over $5.58 million, while Monaco Asset Management SAM holds 4.87% of the shares totaling 9.26 million with a market value of $5.33 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by ROBIN HOWARD W,the company’sPresident & CEO. SEC filings show that ROBIN HOWARD W sold 20,033 shares of the company’s common stock on Feb 20 ’24 at a price of $0.68 per share for a total of $13622.0. Following the sale, the insider now owns 0.88 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Feb 20 ’24 that Zalevsky Jonathan (Chief R&D Officer) sold a total of 9,014 shares of the company’s common stock. The trade occurred on Feb 20 ’24 and was made at $0.68 per share for $6130.0. Following the transaction, the insider now directly holds 0.27 million shares of the NKTR stock.
Still, SEC filings show that on Feb 20 ’24, Wilson Mark Andrew (Chief Legal Officer) disposed off 7,606 shares at an average price of $0.68 for $5172.0. The insider now directly holds 236,674 shares of Nektar Therapeutics (NKTR).
